🚨 Avance en enfermedades raras

China aprueba Selumetinib para NF1-PN, ampliando su uso de niños (3+) a adultos. Inhibidor de MEK con buen control tumoral y mejora de síntomas

💡 Más opciones de tratamiento a lo largo de la vida

⚠️ Solo educativo

#NF1 #RareDisease #Selumetinib #Oncology #ChinaNMPA

Koselugo（セルトメチニブ）、神経線維腫症1型成人患者に対する初のFDA承認薬に — 第3相KOMET試験結果に基づく | STELLANEWS.LIFE アストラゼネカ傘下のアレクシオンは、神経線維腫症1型（NF1）に伴う症候性・手術不能な神経叢神経線維腫を有する成人に対し、MEK阻害薬Koselugo（セルトメチニブ）がFDAの承認を取得したと発表。KOMET試験で20％の奏効率を示し、治療選択肢が拡大。

FDA approves AstraZeneca’s Koselugo (selumetinib) for adults with neurofibromatosis type 1 (NF1).

🔗 Full article: stellanews.life/technology_c...

#Koselugo #Selumetinib #NF1 #AstraZeneca #Alexion #RareDisease #FDAApproval #MEKinhibitor #ClinicalTrials

Koselugo (selumetinib) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento Infarmed

Koselugo (selumetinib) | Relatório de avaliação de financiamento público disponível na Infomed | Deferimento
swki.me/IJj3pgD9

#infarmed #medicamentos #financiamentopublico #Koselugo #selumetinib

Just talked the my oncologist and I’m making the switch from #selumetinib to #mirdametinib

#nf1 #neurofibromatosis

Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial - Nature Medicine In a phase 2 trial of adults with neurofibromatosis type 1 and inoperable/growing plexiform neurofibromas, treatment with the MEK inhibitor selumetinib resulted in an objective response rate of 63.6% ...

In a phase 2 trial of adults with #neurofibromatosis type 1 and inoperable plexiform neurofibromas, the #MEK inhibitor #selumetinib shows an ORR of 63.6% & improved patient outcomes with additional biopsy data on drug activity. @nature.bsky.social

www.nature.com/articles/s41...

#MedSky🧪 #Childhoodcancer # Neurosky #pedsky #publichealth The MEK inhibitor #selumetinib induces objective responses and provides clinical benefit in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs)